Clinical Trial Update: Low-dose IL-2 for Treg Expansion and Tolerance (LITE) [Phase 4]

View source ↗

Summary

A Phase 4 trial investigating low-dose IL-2 to expand regulatory T cells and promote tolerance in transplantation and liver disease, which has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Liver Diseases
• Transplantation

Drugs mentioned

• low-dose IL-2 (interleukin-2)

Snippet

Sponsor: King's College London | Conditions: Transplantation, Liver Diseases | Phase 4 | Status: TERMINATED